Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Seborrheic keratosis with basal clear cells: Report of a case and review of the literature.

Manzotti C, Ríos Martín JJ, Gutiérrez Domingo Á, Gutiérrez Cierco JL, González Cámpora R.

J Cutan Pathol. 2017 Jun;44(6):600-602. doi: 10.1111/cup.12936. Epub 2017 Apr 12. No abstract available.

PMID:
28401581
2.

Evaluation of Levothyroxine Bioavailability after Oral Administration of a Fixed Combination of Soy Isoflavones in Post-menopausal Female Volunteers.

Persiani S, Sala F, Manzotti C, Colovic M, Zangarini M, Donazzolo Y, Barbetta B, Vitalini C, Giacovelli G, Benvenuti C, Rovati LC.

Drug Res (Stuttg). 2016 Mar;66(3):136-40. doi: 10.1055/s-0035-1555784. Epub 2015 Jun 30.

PMID:
26125285
3.

IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells.

Attridge K, Kenefeck R, Wardzinski L, Qureshi OS, Wang CJ, Manzotti C, Okkenhaug K, Walker LS.

J Immunol. 2014 Mar 1;192(5):2195-201. doi: 10.4049/jimmunol.1302082. Epub 2014 Jan 27.

4.

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells.

Wang CJ, Kenefeck R, Wardzinski L, Attridge K, Manzotti C, Schmidt EM, Qureshi OS, Sansom DM, Walker LS.

J Immunol. 2012 Aug 1;189(3):1118-22. doi: 10.4049/jimmunol.1200972. Epub 2012 Jun 29.

5.

IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis.

Attridge K, Wang CJ, Wardzinski L, Kenefeck R, Chamberlain JL, Manzotti C, Kopf M, Walker LS.

Blood. 2012 May 17;119(20):4656-64. doi: 10.1182/blood-2011-10-388546. Epub 2012 Mar 22.

6.

Immune regulation by CTLA-4--relevance to autoimmune diabetes in a transgenic mouse model.

Wang CJ, Schmidt EM, Attridge K, Kenefeck R, Wardzinski L, Chamberlain JL, Soulier A, Clough LE, Manzotti CN, Narendran P, Walker LS.

Diabetes Metab Res Rev. 2011 Nov;27(8):946-50. doi: 10.1002/dmrr.1277.

PMID:
22069290
7.

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.

Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM.

Science. 2011 Apr 29;332(6029):600-3. doi: 10.1126/science.1202947. Epub 2011 Apr 7.

8.

The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo.

Brunelli D, Tavecchio M, Falcioni C, Frapolli R, Erba E, Iori R, Rollin P, Barillari J, Manzotti C, Morazzoni P, D'Incalci M.

Biochem Pharmacol. 2010 Apr 15;79(8):1141-8. doi: 10.1016/j.bcp.2009.12.008. Epub 2009 Dec 16.

PMID:
20006591
9.

Development and validation of a LC-MS/MS method for the determination of the novel oral 1,14 substituted taxane derivatives, IDN 5738 and IDN 5839, in mouse plasma and its application to the pharmacokinetic study.

Marangon E, Falcioni C, Manzotti C, Fontana G, D'Incalci M, Zucchetti M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 15;877(32):4147-53. doi: 10.1016/j.jchromb.2009.10.016. Epub 2009 Oct 23.

PMID:
19906566
10.

Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3.

Zheng Y, Manzotti CN, Burke F, Dussably L, Qureshi O, Walker LS, Sansom DM.

J Immunol. 2008 Aug 1;181(3):1683-91.

11.

Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.

Beretta GL, Petrangolini G, De Cesare M, Pratesi G, Perego P, Tinelli S, Tortoreto M, Zucchetti M, Frapolli R, Bello E, Manzotti C, Fontana G, Bombardelli E, Battaglia A, Samorì C, Zunino F.

Cancer Res. 2006 Nov 15;66(22):10976-82.

12.

Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.

Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, Morazzoni P, Zucchetti M.

Drug Metab Dispos. 2006 Dec;34(12):2028-35. Epub 2006 Sep 8.

13.

Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86.

Manzotti CN, Liu MK, Burke F, Dussably L, Zheng Y, Sansom DM.

Eur J Immunol. 2006 Jun;36(6):1413-22.

14.

[Renal failure in diabetics: is creatinine sufficient for detecting it?].

de Frutos E, Lorenz-Castañé G, Manzotti C, Espínola-Rodríguez A.

Aten Primaria. 2005 Dec;36(10):588. Spanish. No abstract available.

15.

Pharmacokinetic measurements of IDN 5390 using electrospray ionization tandem mass spectrometry: structure characterization and quantification in dog plasma.

Song L, Prey JD, Xue J, Kanter P, Manzotti C, Bombardelli E, Morazzoni P, Pendyala L.

Rapid Commun Mass Spectrom. 2005;19(24):3617-25.

PMID:
16299696
16.

Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells.

Mead KI, Zheng Y, Manzotti CN, Perry LC, Liu MK, Burke F, Powner DJ, Wakelam MJ, Sansom DM.

J Immunol. 2005 Apr 15;174(8):4803-11.

17.

CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells.

Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, Sansom DM.

J Immunol. 2004 Mar 1;172(5):2778-84.

18.

Identification of a secondary zinc-binding site in staphylococcal enterotoxin C2. Implications for superantigen recognition.

Papageorgiou AC, Baker MD, McLeod JD, Goda SK, Manzotti CN, Sansom DM, Tranter HS, Acharya KR.

J Biol Chem. 2004 Jan 9;279(2):1297-303. Epub 2003 Oct 14.

19.

What's the difference between CD80 and CD86?

Sansom DM, Manzotti CN, Zheng Y.

Trends Immunol. 2003 Jun;24(6):314-9. Review.

PMID:
12810107
20.

Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.

Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, Sansom DM.

Eur J Immunol. 2002 Oct;32(10):2888-96.

21.

Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity.

Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G, Torriani D, Randisi E, Cavagnoli R, Sala F, Giuliani FC, Spinelli S.

Tumori. 2001 Nov-Dec;87(6):407-16.

PMID:
11989596
22.

In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma.

Riccardi A, Meco D, Ferlini C, Servidei T, Carelli G, Segni G, Manzotti C, Riccardi R.

Cancer Chemother Pharmacol. 2001 Jun;47(6):498-504.

PMID:
11459202
23.

Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions.

Colella G, Pennati M, Bearzatto A, Leone R, Colangelo D, Manzotti C, Daidone MG, Zaffaroni N.

Br J Cancer. 2001 May 18;84(10):1387-90.

24.

The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.

Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C, Riccardi R.

Eur J Cancer. 2001 May;37(7):930-8.

PMID:
11313183
25.
26.

BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.

Manzotti C, Pratesi G, Menta E, Di Domenico R, Cavalletti E, Fiebig HH, Kelland LR, Farrell N, Polizzi D, Supino R, Pezzoni G, Zunino F.

Clin Cancer Res. 2000 Jul;6(7):2626-34.

27.

Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines.

Roberts JD, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L, Farrell N.

J Inorg Biochem. 1999 Oct;77(1-2):47-50.

PMID:
10626353
28.

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.

Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F.

Br J Cancer. 1999 Aug;80(12):1912-9.

29.

A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.

Perego P, Caserini C, Gatti L, Carenini N, Romanelli S, Supino R, Colangelo D, Viano I, Leone R, Spinelli S, Pezzoni G, Manzotti C, Farrell N, Zunino F.

Mol Pharmacol. 1999 Mar;55(3):528-34. Erratum in: Mol Pharmacol 1999 Jun;55(6):1108.

30.

Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion.

Manzotti C, Audisio RA, Pratesi G.

Clin Exp Metastasis. 1993 Jan;11(1):5-14. Review.

PMID:
8422706
31.
32.

Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft.

Pratesi G, Manzotti C, Tortoreto M, Audisio RA, Zunino F.

Br J Cancer. 1991 Jan;63(1):71-4.

33.

Effect of amrinone on anthracycline-induced lethal and cardiac toxicity in mice and rats.

Villani F, Manzotti C, Mella M, Monti E, Savi G, Zunino F.

Med Oncol Tumor Pharmacother. 1990;7(4):227-32.

PMID:
2283890
34.

Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts.

Pratesi G, Manzotti C, Tortoreto M, Prosperi E, Zunino F.

Tumori. 1989 Feb 28;75(1):60-5.

PMID:
2711477
35.

Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).

Pratesi G, Manzotti C, Damia G, D'Incalci M.

Br J Cancer. 1988 Aug;58(2):144-6.

36.

Birth weight and natural selection: an example of selection relaxation in man.

Ulizzi L, Manzotti C.

Hum Hered. 1988;38(3):129-35.

PMID:
3397065
37.

Supplemental Content

Loading ...
Support Center